Clinical trial
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With…
NCT00478218 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00478218 |
|---|---|
| Title | Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma |
| Official title | A Phase II Trial of Revlimid, Cyclophosphamide, and Dexamethasone in Patients With > Newly Diagnosed Active Multiple Myeloma |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | cyclophosphamide, dexamethasone, lenalidomide |
| Enrollment | 53 |
| Start date | Jul 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Apr 1, 2011 |
| First posted | May 24, 2007 |
| Last update posted | Aug 31, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: